Specific ablation of PDGFRβ-overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models

Seok Jae Lee; Soohyun Kim; Dong Hyun Jo; Chang Sik Cho; Su Ree Kim; Dongmin Kang; Jisu Chae; Duck Kyun Yoo; Suji Ha; Junho Chung; Jeong Hun Kim

doi:10.1038/s43856-021-00059-3

Communications Medicine (Dec 2021)

Specific ablation of PDGFRβ-overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models

Seok Jae Lee,
Soohyun Kim,
Dong Hyun Jo,
Chang Sik Cho,
Su Ree Kim,
Dongmin Kang,
Jisu Chae,
Duck Kyun Yoo,
Suji Ha,
Junho Chung,
Jeong Hun Kim

Affiliations

Seok Jae Lee: Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital
Soohyun Kim: Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine
Dong Hyun Jo: Department of Anatomy & Cell Biology, Seoul National University College of Medicine
Chang Sik Cho: Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital
Su Ree Kim: Department of Life Science, Fluorescence Core Imaging Center, Ewha Womans University
Dongmin Kang: Department of Life Science, Fluorescence Core Imaging Center, Ewha Womans University
Jisu Chae: Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine
Duck Kyun Yoo: Department of Biomedical Sciences, Seoul National University College of Medicine
Suji Ha: Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine
Junho Chung: Department of Biomedical Sciences, Seoul National University College of Medicine
Jeong Hun Kim: Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital

DOI: https://doi.org/10.1038/s43856-021-00059-3
Journal volume & issue: Vol. 1, no. 1
pp. 1 – 12

Abstract

Read online

Lee et al. use an antibody-drug conjugate to treat pathologic ocular neovascularization in mouse models. The antibody-drug conjugate targets PDGFRβ-expressing pericytes, with similar therapeutic effects to an anti-VEGF agent and with limited unwanted toxicity.

Published in Communications Medicine

ISSN: 2730-664X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/commsmed/

About the journal